A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded a decrease of -91.09%. However, over the last six months, the performance has been weaker by 6.84%. The price of RNAZ decreased -4.50% over the last 30 days. And in the last five days, it has fallen by -4.18%.
In terms of market performance, TransCode Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $19.42 on 11/08/23, and the lowest value was recorded at $0.22 on 08/14/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of RNAZ Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. TransCode Therapeutics Inc’s current trading price is -96.98% away from its 52-week high, while its distance from the 52-week low is 171.99%. The stock’s price range during this period has varied between$0.22 and $19.42. The TransCode Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.58 million for the day, a figure considerably lower than their average daily volume of 2.03 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
TransCode Therapeutics Inc (RNAZ) has experienced a quarterly rise of 93.38% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 10.15M and boasts a workforce of 10 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5869, with a change in price of -0.7725. Similarly, TransCode Therapeutics Inc recorded 1,547,629 in trading volume during the last 100 days, posting a change of -56.80%.
RNAZ’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
As of today, TransCode Therapeutics Inc’s raw stochastic average for the last 50 days stands at 63.20%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 47.40%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 59.58% and 60.79%, respectively.
